AZR Azora Therapeutics, Inc. (DE)
Pharmaceutical Preparations · Nasdaq · SEC CIK 1513525 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,397.4%
TTM EPS YoY76.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-855.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets22.4%
Debt / equity—
Current ratio4.43x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.13x
Accruals ratio-742.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $2.62M | $3.23M |
| SG&A expense | $5.18M | $5.06M |
| Operating income | -$7.80M | -$8.28M |
| Pretax income | -$7.98M | -$13.20M |
| Net income | -$7.98M | -$13.20M |
| EPS (basic) | -11.93 | -68.01 |
| EPS (diluted) | -11.93 | -68.01 |
| Weighted avg. shares (diluted) | 668,630 | 194,059 |
| Balance sheet | ||
| Cash & equivalents | $5.88M | $3.75M |
| Current assets | $6.18M | $4.06M |
| Intangibles | $3,000 | $3,348 |
| Total assets | $6.67M | $5.04M |
| Current liabilities | $1.40M | $975,858 |
| Total liabilities | $1.40M | $975,858 |
| Shareholders' equity | $5.28M | $4.07M |
| Shares outstanding | 1.11M | 258,826 |
| Cash flow statement | ||
| Operating cash flow | -$6.49M | -$6.92M |
| Investing cash flow | $150,000 | — |
| Financing cash flow | $8.47M | $7.85M |
| Stock-based compensation | $676,200 | $796,831 |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.